Skip to main content
Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma
Journal of the Advanced Practitioner in Oncology (2016)
  • Sandra Kurtin, University of Arizona
  • Kathleen Colson, Harvard University
  • Joseph D Tariman, PhD, DePaul University
  • Beth Faiman, Cleveland Clinic Myeloma Program
  • Elizabeth Finley-Oliver, Moffitt Cancer Center
Multiple myeloma (MM) is a plasma cell disease characterized by the overproduction of monoclonal proteins, associated end-organ damage, and variable disease trajectory with variable intervals of treatment response and relapse. Although MM is considered incurable, strides made in understanding the pathobiology and molecular underpinnings of the disease over the last decade offer hope for a cure in some cases. Survival rates have continued to improve as a result of novel agents, improved supportive care, and integration of autologous hematopoietic stem cell transplant. Adherence, persistence, and treatment fatigue issues must be addressed.
  • myeloma,
  • treatment fatigue,
  • adherence,
  • cancer
Publication Date
Winter March 1, 2016
doi: 10.6004/jadpro.2016.7.2.16
Citation Information
Sandra Kurtin, Kathleen Colson, Joseph D Tariman, Beth Faiman, et al.. "Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma" Journal of the Advanced Practitioner in Oncology Vol. 7 Iss. 1 (2016) p. 71 - 77
Available at:
Creative Commons license
Creative Commons License
This work is licensed under a Creative Commons CC_BY-NC-ND International License.